Nineteen infertile women who completed GnRH agonist treatment for endometriosis were reevaluated clinically an average of 39 months(30~46 months) later. Patients were treated with a delayed-release preparation of triptorelin in biodegradable
microcapsules (Decapeptyl-CR, Ferring AB) administered intramuscularly at four week intervals for a period of four months. The extent of endometriosis was staged laparoscopically before treatment: stage I (revised American Fertility Society
classification) in 2 patients, stage II in 2, stage III in 7, and stage IV in 8.
Of 17 patients with tubal patency, 10 conceived with no adjuvant therapy, 3 after adjuvant operation, 1 by GIFT, and 8 by IVF. Of 10 patients who conceived with no adjuvant theapy, 7 patients conceived within 6 months after GnRH agonist therapy.
The recurrence. Of symptoms was reported by 52%(9/17). There was none whose symptoms at last follow-up were aggravated compared with those before treatment.
In conclusion, GuRH agonist treatment for endometriosis is effective in abating symptomatic pain and enhancing fertility in infertile patients.
|